文献速递免疫规划慢病防控与筛查卫生政策与健康促进

埃塞俄比亚四价与非价人乳头瘤病毒疫苗的成本效果分析

Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
PubMed 文献 · Vaccine · 2022-03-02

研究采用静态马尔可夫队列模型模拟埃塞俄比亚12岁女孩(N=100,000)HPV感染至宫颈癌的进展,比较9vHPV与4vHPV疫苗的成本效果。9vHPV疫苗在每剂6.9美元时,每获得一个QALY的增量成本效果比为454美元,低于埃塞俄比亚人均GDP的一倍。结论认为只要每剂价格不超过15美元,9vHPV疫苗在埃塞俄比亚具有成本效果。

要点

  • 9vHPV相比4vHPV每获得一个QALY的ICER为454美元,低于人均GDP的一倍。
  • 9vHPV每剂价格不超过8.4美元和15美元时,分别在一倍和三倍人均GDP阈值下保持极具成本效果和具有成本效果。
  • ICER对QALY贴现率的变化最敏感。

核心结论

  • 与4vHPV疫苗相比,9vHPV疫苗在埃塞俄比亚具有成本效果,前提是每剂价格不超过15美元。

研究设计与样本

  • 静态马尔可夫队列模型模拟埃塞俄比亚12岁女孩(N=100,000)从HPV感染至宫颈癌的进展,模型运行至100岁,周期长度1年。
  • 采用单因素和概率敏感性分析探讨模型稳健性和参数不确定性。
  • 考虑每获得一个QALY的一倍和三倍人均GDP作为成本效果阈值。

主要发现

  • 在每剂6.9美元价格下,9vHPV疫苗相比4vHPV疫苗每获得一个QALY的ICER为454美元,低于埃塞俄比亚人均GDP的一倍。
  • ICER对QALY贴现率的变化最敏感。
  • 在一倍人均GDP阈值下,9vHPV疫苗每剂价格不超过8.4美元时保持极具成本效果;在三倍人均GDP阈值下,每剂价格不超过15美元时保持具有成本效果。

关键数值与推荐

  • 成本效果阈值为一倍和三倍人均GDP每获得一个QALY。
  • 9vHPV疫苗相比4vHPV疫苗的ICER为454美元/QALY(每剂价格6.9美元时)。
  • 9vHPV疫苗每剂价格不超过8.4美元时(一倍人均GDP阈值)保持极具成本效果,不超过15美元时(三倍人均GDP阈值)保持具有成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Ethiopia, cervical cancer is the second most common cancer among women of the reproductive age group. Since 2018, the quadrivalent human papillomavirus (4vHPV) vaccine targeting four HPV types (6/11/16/18) has been introduced in the national immunization program in Ethiopia. Currently, however, a nonavalent HPV (9vHPV) vaccine which provides broader protection against nine HPV types ( 6/11/16/18/31/33/45/52/58) is available for global use. Our study, therefore, aims to estimate the cost-effectiveness of 9vHPV vaccine compared to the current HPV vaccination program in Ethiopia. METHOD: A static Markov cohort model was used to simulate the progression of HPV infection to cervical cancer for a cohort of 12-years-old girls (N = 100,000) in Ethiopia. The model ran up to the age of 100 years, with a cycle length of 1 year. One-way and probabilistic sensitivity analyses were used to explore the robustness of the model and uncertainties around the parameters included in the model. Cost-effectiveness thresholds of one and three times gross domestic product (GDP) per quality-adjusted life-year (QALY) gained were considered. RESULTS: At a price of US$ 6.9, the incremental cost-effectiveness ratio (ICER) per QALY gained for the 9vHPV vaccine was US$ 454 compared to the 4vHPV vaccine, which is less than one times GDP per capita of Ethiopia. The ICER was most sensitive to the change in the discount rate of QALYs. Compared to 4vHPV vaccine, for 9vHPV vaccine to remain very cost-effective and cost-effective, its price per dose should not exceed US$ 8.4 and US$ 15, respectively, at a threshold of one and three times GDP per capita. CONCLUSION: Compared to the 4vHPV vaccine, the 9vHPV vaccine is a cost-effective option in Ethiopia, given that its price per dose does not exceed US$15.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wondimu A, Postma MJ, van Hulst M, et al. Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia. Vaccine. 2022. PMID: 35248423. doi:10.1016/j.vaccine.2022.02.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。